383
Participants
Start Date
February 22, 2016
Primary Completion Date
October 26, 2021
Study Completion Date
September 1, 2025
Monalizumab
Participants will receive IV infusion of monalizumab as stated in arm description.
Durvalumab
Participants will receive IV infusion of durvalumab as stated in arm description.
Cetuximab
Participants will receive IV infusion of cetuximab as stated in arm description.
mFOLFOX6
Participants will receive IV infusion of mFOLFOX as stated in arm description.
Bevacizumab
Participants will receive IV infusion of bevacizumab as stated in arm description.
Research Site, Grafton
Research Site, Brussels
Research Site, Blacktown
Research Site, Waratah
Research Site, Edegem
Research Site, Leuven
Research Site, Clayton
Research Site, Debrecen
Research Site, New York
Research Site, The Bronx
Research Site, New Hyde Park
Research Site, Marseille
Research Site, Milan
Research Site, Milan
Research Site, Baltimore
Research Site, Madrid
Research Site, Madrid
Research Site, Málaga
Research Site, Pamplona
Research Site, Tampa
Research Site, Birmingham
Research Site, Nashville
Research Site, Seville
Research Site, Nantes
Research Site, Detroit
Research Site, Chicago
Research Site, Dallas
Research Site, San Antonio
Research Site, Aurora
Research Site, Salt Lake City
Research Site, Scottsdale
Research Site, Los Angeles
Research Site, Santa Monica
Research Site, Duarte
Research Site, La Jolla
Research Site, Sacramento
Research Site, Boston
Research Site, New Brunswick
Research Site, Providence
Research Site, Vancouver
Research Site, Toronto
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, London
Research Site, Sutton
Lead Sponsor
MedImmune LLC
INDUSTRY